PURPOSE: To determine the impact of substratum stiffness and latrunculin-B (Lat-B), on the expression of several matrix proteins that are associated with glaucoma. METHODS: Human trabecular meshwork (HTM) cells were cultured on hydrogels possessing stiffness values mimicking those found in normal (5 kPa) and glaucomatous meshworks (75 kPa), or tissue culture polystyrene (TCP; >1 GPa). Cells were treated with 2.0 μM Lat-B in dimethyl sulfoxide (DMSO) or DMSO alone. RT-PCR was used to determine the impact of substratum stiffness and/or Lat-B treatment on the expression of secreted protein, acidic, cysteine rich (SPARC), myocilin, angiopoietin-like factor (ANGPTL)-7, and transglutaminase (TGM)-2. Immunofluorescence was used to assess changes in protein expression. RESULTS: SPARC and myocilin mRNA expression were dramatically increased on the 75 kPa hydrogels and decreased on the 5 kPa hydrogels in comparison to TCP. In contrast, ANGPTL-7 mRNA and TGM-2 mRNA was decreased on the 75 kPa and 5 kPa hydrogels, respectively, in comparison with TCP. Treatment with Lat-B dramatically downregulated both SPARC and myocilin on 75 kPa hydrogels. In contrast, cells grown on TCP produced greater or similar amounts of SPARC and myocilin mRNA after Lat-B treatment. SPARC and myocilin protein expression paralleled changes in mRNA expression. CONCLUSIONS: Substratum stiffness impacts HTM matrix gene and protein expression and modulates the impact of Lat-B treatment on the expression of these matrix proteins. Integrating the use of biologically relevant substratum stiffness in the conduction of in vitro experiments gives important insights into HTM cell response to drugs that may more accurately predict responses observed in vivo.
PURPOSE: To determine the impact of substratum stiffness and latrunculin-B (Lat-B), on the expression of several matrix proteins that are associated with glaucoma. METHODS:Human trabecular meshwork (HTM) cells were cultured on hydrogels possessing stiffness values mimicking those found in normal (5 kPa) and glaucomatous meshworks (75 kPa), or tissue culture polystyrene (TCP; >1 GPa). Cells were treated with 2.0 μM Lat-B in dimethyl sulfoxide (DMSO) or DMSO alone. RT-PCR was used to determine the impact of substratum stiffness and/or Lat-B treatment on the expression of secreted protein, acidic, cysteine rich (SPARC), myocilin, angiopoietin-like factor (ANGPTL)-7, and transglutaminase (TGM)-2. Immunofluorescence was used to assess changes in protein expression. RESULTS:SPARC and myocilin mRNA expression were dramatically increased on the 75 kPa hydrogels and decreased on the 5 kPa hydrogels in comparison to TCP. In contrast, ANGPTL-7 mRNA and TGM-2 mRNA was decreased on the 75 kPa and 5 kPa hydrogels, respectively, in comparison with TCP. Treatment with Lat-B dramatically downregulated both SPARC and myocilin on 75 kPa hydrogels. In contrast, cells grown on TCP produced greater or similar amounts of SPARC and myocilin mRNA after Lat-B treatment. SPARC and myocilin protein expression paralleled changes in mRNA expression. CONCLUSIONS: Substratum stiffness impacts HTM matrix gene and protein expression and modulates the impact of Lat-B treatment on the expression of these matrix proteins. Integrating the use of biologically relevant substratum stiffness in the conduction of in vitro experiments gives important insights into HTM cell response to drugs that may more accurately predict responses observed in vivo.
Authors: E M Stone; J H Fingert; W L Alward; T D Nguyen; J R Polansky; S L Sunden; D Nishimura; A F Clark; A Nystuen; B E Nichols; D A Mackey; R Ritch; J W Kalenak; E R Craven; V C Sheffield Journal: Science Date: 1997-01-31 Impact factor: 47.728
Authors: E Lütjen-Drecoll; C A May; J R Polansky; D H Johnson; H Bloemendal; T D Nguyen Journal: Invest Ophthalmol Vis Sci Date: 1998-03 Impact factor: 4.799
Authors: R H Pichler; C Hugo; S J Shankland; M J Reed; J A Bassuk; T F Andoh; D M Lombardi; S M Schwartz; W M Bennett; C E Alpers; E H Sage; R J Johnson; W G Couser Journal: Kidney Int Date: 1996-12 Impact factor: 10.612
Authors: Maryam Ali; VijayKrishna Raghunathan; Jennifer Y Li; Christopher J Murphy; Sara M Thomasy Journal: Exp Eye Res Date: 2016-09-14 Impact factor: 3.467
Authors: Joshua T Morgan; Joshua A Wood; Naomi J Walker; Vijay Krishna Raghunathan; Dori L Borjesson; Christopher J Murphy; Paul Russell Journal: J Ocul Pharmacol Ther Date: 2014-01-23 Impact factor: 2.671
Authors: Ted S Acott; Mary J Kelley; Kate E Keller; Janice A Vranka; Diala W Abu-Hassan; Xinbo Li; Mini Aga; John M Bradley Journal: J Ocul Pharmacol Ther Date: 2014-01-08 Impact factor: 2.671
Authors: Vijaykrishna Raghunathan; Clayton McKee; Wai Cheung; Rachel Naik; Paul F Nealey; Paul Russell; Christopher J Murphy Journal: Tissue Eng Part A Date: 2013-08 Impact factor: 3.845
Authors: Sara M Thomasy; Vijay Krishna Raghunathan; Hidetaka Miyagi; Alexander T Evashenk; Jasmyne C Sermeno; Geneva K Tripp; Joshua T Morgan; Christopher J Murphy Journal: Exp Eye Res Date: 2018-02-06 Impact factor: 3.467
Authors: Joshua T Morgan; Vijay Krishna Raghunathan; Sara M Thomasy; Christopher J Murphy; Paul Russell Journal: Biotechniques Date: 2014-01 Impact factor: 1.993
Authors: Vijay Krishna Raghunathan; Joshua T Morgan; Britta Dreier; Christopher M Reilly; Sara M Thomasy; Joshua A Wood; Irene Ly; Binh C Tuyen; Marissa Hughbanks; Christopher J Murphy; Paul Russell Journal: Invest Ophthalmol Vis Sci Date: 2013-01-14 Impact factor: 4.799